Matt Kumeta

Matt Kumeta
T: +44 (0) 121 654 5013

Matt is an Analyst at Alantra.

His chief responsibilities are to produce detailed analysis of transaction trends and to provide bespoke research to support business development and deal delivery. 

Matt is a member of the Healthcare sector team. He also has a focus on our business development activities in the East Midlands. Recent deals include advising on the sale of 4Ways, the acquisition of Cornerstone Healthcare Group, and advising Spectris plc on its £163m acquisition of Concept Life Sciences.

Matt has a MSc (Distinction) in Banking & Finance from Queen Mary, University of London and an undergraduate degree in Money Banking & Finance from the University of Birmingham.

When he's not at work, Matt enjoys playing golf, squash and hockey and is a member of Edgbaston's hockey club. He also likes watching rugby and playing the guitar and saxophone.

Alantra appoints experienced partner to head up its UK Real Estate & Hospitality team

Alantra has appointed Hoong Wey Woon as a Partner to head up its UK Real Estate & Hospitality team.  

Alantra advises Strong Roots on securing over €15.5m of investment

Alantra advises Strong Roots, one of the UK’s fastest-growing food companies, on securing over €15.5m of investment 

Alantra advises i2S on its sale to Gfi Informatique

Alantra advises Portuguese IT firm, i2S, on its sale to Gfi Informatique 

Alantra expands its technology sector team with two senior appointments

Alantra has expanded its Technology Media and Telecoms (TMT) sector team with two senior appointments. James Chapman-Andrews joins as Partner and Head of UK TMT and Simon Devonshire OBE, joins as Technology Industry Adviser.  

Alantra advises on sale of 3P Biopharmaceuticals to Keensight Capital

We advised Cinfa and the rest of the shareholders on the sale of 3P Biopharmaceuticals to Keensight Capital, a European growth private equity fund with deep expertise in healthcare.